Expert discusses how understanding and promoting awareness of CKD stages enables earlier intervention and better management of disease progression and cardiovascular risk.
A historical perspective on traditional factor replacement therapies, tracing their development, successes, and ongoing limitations such as short half-life, infusion requirements, and inhibitor formation.
Expert discusses how the high prevalence of undiagnosed CKD creates a significant clinical and financial burden that can be alleviated through earlier detection and intervention.
Milliman’s Jennifer Cruz says plans are losing rebates because of steep price discounts negotiated under the Inflation Reduction Act. but that they need to be sure that renegotiation of rebate guarantees doesn’t get too broad.
Pharmacy benefit managers are approaching health plans with value-based contracts that consider lower costs on the medical benefit of the insurance, says Jennifer Cruz of Milliman.
AI and virtual care revolutionize dermatology, enhancing melanoma detection, expanding patient access and improving efficiency in clinical practices.
Nearly all women experience a decrease in libido as they go through perimenopause and menopause, but it remains unaddressed
Fulton County leaders tackle healthcare disparities by forming partnerships and enhancing access, aiming for equitable health solutions in Georgia. Pamela Roshell, Ph.D., and LaTrina Foster spoke with Managed Healthcare Executive in this second part of a two-part video interview series.
An expert discusses how the CLEAR Outcomes trial data demonstrated that bempedoic acid effectively reduces cardiovascular events by 13% in nearly 14,000 statin-intolerant patients over 4.9 years with excellent tolerability, while long-term data from PCSK9 inhibitor studies such as the FOURIER trial show sustained safety and efficacy over five to eight years with the principle that “lower for longer is better,” as patients who started treatment earlier maintained cardiovascular protection advantages that late-starters could never catch up to despite achieving similar LDL reductions.
